Organon Pharma Indonesia Tbk. vs Samudera Indonesia Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Samudera Indonesia Tbk. trades at Rp392 (market cap 6.29T, 52.26M 24h volume). The key difference: Samudera Indonesia Tbk. is far larger — about 60.2× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SMDR | |
|---|---|---|
Market Cap | 104.4B | 6.29T |
Volume | — | 52.26M |
Lot | — | 522.58K |
Turnover | — | 19.94B |
Average Price | — | 381.6 |
Value | — | 19.94B |
Indicative Equilibrium Price | — | 392 |
Indicative Equilibrium Volume | — | 25.18K |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Samudera Indonesia Tbk (the Company) was established on November 13, 1964 under the framework of the Domestic Capital Investment Law No. 6 of 1968 as amended by Law No. 12 of 1970, based on notarial deed No. 33 of Soeleman Ardjasasmita, S.H. PT. Samudera Indonesia Tbk offers a full range of transportation services from feeder, tanker, offshore and land transportation for containers and heavy equipment to container depots and warehousing as well as freight forwarding services. In 1997, SSL, a subsidiary, listed on the Singapore Exchange Securities Trading Ltd.
Read more on SMDR →